First Read: Nuvation Bio Inc "New Phase III Study in IDH1 Glioma -..."

研报英文原文证据摘录

First Read: Nuvation Bio Inc "New Phase III Study in IDH1 Glioma -..."

Forecast returns

Forecast price appreciation 20.7%

Forecast dividend yield 0.0%

Forecast stock return 20.7%

Market return assumption 9.2%

Forecast excess return 11.5%

Company Description

Nuvation Bio is a clinical-stage biopharmaceutical company dedicated to developing next-

generation oncology therapies for patients with some of the most challenging cancers. The

company approach combines deep scientific expertise with innovative drug design to create

differentiated treatments that target critical gaps in current cancer care. By focusing on areas

of high unmet need, Nuvation Bio aims to deliver transformative medicines that improve

patient outcomes and advance the standard of care in oncology.

Valuation Method and Risk Statement

We value NUVB using a risk-adjusted EV/2035 sales multiple. Key risks include: Clinical Risk:

Drug candidates may fail in clinical trials due to lack of efficacy or safety concerns, eliminating

significant expected value; Regulatory Risk: Approval is subject to complex and uncertain

regulatory processes; delays or rejections can materially impact timelines and valuations;

Financing Risk: Small cap biotech companies often rely on external capital; adverse market

conditions may force dilutive financings or limit access to funding; Competitive Risk: Larger,

better funded competitors or faster moving peers may develop superior therapies or reach

the market first; Pricing & Reimbursement Risk: Even approved products may face pricing

pressure, reimbursement challenges, or limited market adoption.

First Read: Nuvation Bio Inc 20 July 2026 ab 3